Search
Defining underserved communities_Infographic_230627.pdf
Boehringer Ingelheim - Whitepaper High throughput cultivation platform microbial strain and process development
Partnering in Infectious Diseases MAY 2024 CORP_0.pdf
Supplier Training Deck - Invoice
Partnering with Boehringer Ingelheim MAY 2023 Corp
Defining underserved communities_Infographic_230627.pdf
Infographic_Defining underserved communities_230627.pdf
Partnering in Immunology & Inflammation MAY 2024 CORP_0.pdf
Partnering in Pain & Mobility MAY 2024 CORP_0.pdf
Boehringer_Ingelheim_auf_einen_Blick_2018.pdf
Boehringer Ingelheim Animal Health Business Unit Factsheet_2.pdf
WISDOM_Infographic_Final_Print Ready.pdf
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
Partnering with Boehringer Ingelheim at BIO-Europe 2024
Learn about partnering with Boehringer Ingelheim at BIO-Europe 2024 and how together we can accelerate innovation in human health
Partnering in Retinal Health HP OCTOBER 2024 CORP_1.pdf
Partnering with Boehringer Ingelheim HP OCTOBER 2024 CORP.pdf
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
The GPP Forum
The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP